The prime objective behind this investigation was to plan a Letrozole enclosed adhesive transdermal patch; since the transdermal route is an outright attractive option concerning its route, convenience and safety. Letrozole, a non-steroidal type II aromatase inhibitor, is reported for treating breast tumours and in postmenopausal women. In this study, few factors confined to formulation such as drug-in-adhesive, enhancers and amount of drug-loaded were investigated. The procedure used supposedly involves, the incarnation of the LET in phospholipids exploiting to a spray dryer. FTIR, X-RD, and DSC techniques which are used to evaluate entrapment efficiency were employed to LET spray-dried powder (LT-SDP). The molecule size, polydispersity file, and the EE were allegedly found to be 284.0 nm, 0.247 and 59.08%. On adding LT-SDP to a cream base with peppermint and olive oil as regular infiltration, the optimized formulation showed superior skin targeting in both in vitro and in vivo observations post-study.In vivo bioavailability studies showed just about four-fold increment in the plasma whereas the mean residence time and half-life were reasonably higher as compared to the LET cream in plain. The in vivo results observed remarkable patch concurrence with the plasma fixations anticipated from the in vitro infiltration. As an outpatient convenience, avoidance of gastrointestinal incompatibility provides suitability for self-administration for breast cancer prevention and treatment.
Single- and Multiple-Dose Pharmacokinetics of a Novel Tetramethylpyrazine Reservoir-Type Transdermal Patch versus Tetramethylpyrazine Phosphate Oral Tablets in Healthy Normal Volunteers, and in Vitro/in Vivo Correlation